Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation
about
Insights into CYP2B6-mediated drug-drug interactionsEfavirenz and the CNS: what we already know and questions that need to be answeredTowards a rational design of solid drug nanoparticles with optimised pharmacological properties.Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.A rapid and selective HPLC-UV method for the quantitation of efavirenz in plasma from patients on concurrent HIV/AIDS and tuberculosis treatments.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersOrganic carbamates in drug design and medicinal chemistryPopulation pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.PharmGKB summary: Efavirenz pathway, pharmacokineticsEffects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsIndividualization of antiretroviral therapy.The pregnane X receptor in tuberculosis therapeutics.Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping indexInhibition of Efavirenz Metabolism by Sertraline and Nortriptyline and Their Effect on Efavirenz Plasma Concentrations.Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid.Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalystEffects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisPopulation Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.A targeted proteomics approach for profiling murine cytochrome P450 expression.Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Pharmacokinetic drug interactions involving Ginkgo biloba.
P2860
Q28078857-17377C08-7C47-4B7A-8AA5-F1533E340C7EQ28085028-21B6E070-753A-492A-888E-2C92777ABDB0Q30372133-9827E6B7-FD0D-497B-91EB-F20E9A21F491Q33798516-F3AB462D-DDAF-4D52-BA18-33C1C5642C6CQ33821729-A868AEEA-BA1C-4721-A668-5183B394011AQ33861268-05417333-6481-4D5A-8D49-184339F6B935Q34457429-F6F26F02-0ADC-4ACD-8E12-75EBA4E0CD3AQ34503553-944FC230-5B17-4BB1-B932-F011EAE70252Q34531724-0F48BA16-7B64-47C6-8FE9-CA014CFB98D2Q34632875-62039462-6CB4-4235-B38D-6FF93C0C6F4AQ34710641-F072F7C7-1BDA-40AD-B7B7-906AF8C81A2EQ34737523-A927CEB5-368C-4A07-9B97-F4EDF90B17C3Q34756398-EAFD8E52-D558-4D08-BFE5-83F47D1CFCBEQ34777808-097C8E82-7D3D-4C00-A68A-DDB38F93F078Q35065867-AC406354-1F65-4D9E-9805-5E61DDA26FE4Q35365543-39655583-835E-46AC-BD3A-38EA6E97E439Q35547723-1D0FD4D3-DBCC-41FE-98EF-0EF94EEDD4BEQ35706069-442C8F5F-24D9-45C7-BF66-E63B7426C63EQ35846912-DDFB5041-9228-4041-83BC-BE60750B6F27Q36406259-455B7729-3609-43CC-89EC-0465445B209BQ36437792-C23ACEBD-4AD1-4582-B1A3-1880EB3CF315Q36441423-5178FE86-DE94-4B26-89F8-A613541EB973Q36451492-63AC040D-A73E-4A10-A22F-C8F4694CFD08Q36562516-A6421627-EAF7-4B4C-8CE4-FB9AE5C276EBQ36571936-91C57A5E-AAAE-438D-B46A-845FEEF03AC9Q36573340-9F88D854-EE45-42AE-B765-2E9C09CA6561Q36887174-525DB47D-F0A9-49B0-93AB-4CAB31C5C1E6Q37126489-A0F8EF74-2047-4F3C-88ED-88DF84F1AFFAQ37153012-9B6ECB15-8063-4A2D-A210-BB76A1FA02E9Q37325589-1C6FC6B3-4251-48EB-8397-CA56D0511EBFQ37358704-C198C830-C5A8-4E76-B629-A65FFBEB80FFQ37422732-889B8362-61B8-47B4-8D19-566DDD25D85DQ37429325-915C1F7A-C4A1-47C5-88BB-16FF0E56DF47Q37466856-D64724F4-6CD1-4814-8A6A-340C781A2681Q37538760-44A2670E-A285-4D28-8405-4735475B759FQ37707721-C106AE2D-DA36-4573-9A60-4C489C9A61B1Q37866298-B61C94A8-557F-490B-8029-DB74E7BD2263Q37948134-8ACE856D-EDFC-49DF-A910-135FD6991C4CQ38051400-4EBF62E7-99E6-4AFB-BC31-7F764CD83095Q38122439-E93E2FCE-BACA-4047-82BB-F2E3E79EB7E0
P2860
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@ast
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@en
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@nl
type
label
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@ast
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@en
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@nl
prefLabel
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@ast
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@en
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@nl
P2093
P2860
P356
P1476
Efavirenz primary and secondar ...... t of efavirenz 7-hydroxylation
@en
P2093
Andrea R Masters
David R Jones
Evan T Ogburn
Yingying Guo
P2860
P304
P356
10.1124/DMD.109.031393
P577
2010-03-24T00:00:00Z